Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IVIG-VImmune
- Development stage
- Unknown
- Lead developer
- Virchow Biotech
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
IVIG-VImmune is an **intravenous immunoglobulin (IVIG)** product designed for the treatment of primary immunodeficiency and potentially other disorders of antibody deficiency. IVIG products are sterile solutions containing pooled immunoglobulin G (IgG) antibodies extracted from the plasma of thousands of healthy donors. The main mechanism of action is to provide passive immunity by supplying functional IgG antibodies, which can neutralize pathogens and modulate the immune response. IVIG is used in a broad range of **immunodeficiency states and autoimmune diseases**, including primary immunodeficiency, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, and others. IVIG-VImmune, specifically, is being studied for its efficacy, safety, and pharmacokinetics in patients with primary immunodeficiency[6].
- Brand names
- IVIG-VImmune
- Other names
- IVIG-VImmune
02
Targets
FCGR3B (Fc gamma receptor III)FCGR2B (Fc gamma receptor IIB)
Beyond the preview
Go deeper on IVIG-VImmune.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IVIG-VImmune.